R. Jeffrey Karnes
Mayo Clinic
CancerInternal medicineRadiologyUrologySurgeryOncologyHazard ratioCystectomyProstateBiochemical recurrenceAndrogen deprivation therapyMetastasisProstatectomyProstate cancerBladder cancerLymph nodeProstate-specific antigenCancer researchRadiation therapyMedicine
Publications 470
#1Jianong Zhang (Fudan University)
#2Kun Gao (Tongji University)H-Index: 5
Last. Huifen Chen (Tongji University)
view all 22 authors...
Mutations in SPOP E3 ligase gene are reportedly associated with genome-wide DNA hypermethylation in prostate cancer (PCa) although the underlying mechanisms remain elusive. Here, we demonstrate that SPOP binds and promotes polyubiquitination and degradation of histone methyltransferase and DNMT interactor GLP. SPOP mutation induces stabilization of GLP and its partner protein G9a and aberrant upregulation of global DNA hypermethylation in cultured PCa cells and primary PCa specimens. Genome-wide...
#2Abhinav KhannaH-Index: 8
Last. Prabin ThapaH-Index: 32
view all 16 authors...
#1Adam B. WeinerH-Index: 14
#2Yang LiuH-Index: 79
Last. R. Jeffrey KarnesH-Index: 70
view all 15 authors...
INTRODUCTION AND OBJECTIVE:Tumors with mutations associated with homologous recombination deficiency (HRD) are uncommon in prostate cancer (PCa) and variably responsive to PARP inhibition. To bette...
#1Nicola FossatiH-Index: 36
#2Giovanni MotterleH-Index: 5
Last. Alessandro NiniH-Index: 13
view all 26 authors...
INTRODUCTION AND OBJECTIVE:Salvage lymph node dissection (SLND) is considered an experimental treatment for patients with nodal recurrence after radical prostatectomy (RP). However, most of them al...
#1Elio MazzoneH-Index: 11
#2Giorgio GandagliaH-Index: 47
Last. R. Jeffrey KarnesH-Index: 70
view all 25 authors...
#1Yu Jiang (University of California, Berkeley)
#2Travis J. Meyers (University of California, Berkeley)H-Index: 8
Last. Janet L. Stanford (UW: University of Washington)H-Index: 98
view all 97 authors...
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide asso...
#1Armando Stabile (UniSR: Vita-Salute San Raffaele University)H-Index: 17
#2Paolo Dell'Oglio (UniSR: Vita-Salute San Raffaele University)H-Index: 28
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 11 authors...
Abstract Background There is a lack of evidence on the ability of magnetic resonance imaging (MRI) of the prostate to detect clinically significant prostate cancer (csPCa) in young patients. Objective We hypothesised that the diagnostic performance of MRI for csPCa varies according to patient's age. To address this, we assessed the variation in the csPCa detection rate of MRI targeted biopsy (MRI-TBx) versus systematic random biopsy (SBx) across different patient ages. Design, setting, and parti...
5 CitationsSource
#1Adam B. Weiner (NU: Northwestern University)H-Index: 14
#2Yang LiuH-Index: 79
Last. R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
view all 16 authors...
BACKGROUND Tumors with mutations associated with homologous recombination deficiency (HRD) are uncommon in prostate cancer (PCa) and variably responsive to PARP inhibition. To better identify tumors with HRD, we developed a transcriptomic signature for HRD in PCa (HRD-P). METHODS By using an established mutational signature, we created and validated HRD-P in six independent PCa cohorts (primary PCa, n = 8224; metastatic castration-resistant PCa [mCRPC], n = 328). Molecular and clinical features ...
#1Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
#2R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
Last. Robert T. Dess (UM: University of Michigan)H-Index: 16
view all 58 authors...
Importance null The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown. null Objective null To compare clinical outcomes among patients with high-risk prostate cancer after definitive treatment. null Design, Setting, and Participants null This retrospective cohort study included patients with high-risk prostate cancer (as defined by the National Comprehensive Cancer Network [NCCN]) and at least 1 adverse clinicopathologic f...
#1Vignesh T. Packiam (UI: University of Iowa)H-Index: 14
#2Craig Labbate (U of C: University of Chicago)H-Index: 3
Last. Igor Frank (Mayo Clinic)H-Index: 63
view all 16 authors...
Abstract Introduction While numerous current clinical trials are testing novel salvage therapies (ST) for patients with recurrent nonmuscle invasive bladder cancer (NMIBC) after bacillus Calmette-Guerin (BCG), the natural history of this disease state has been poorly defined to date. Herein, we evaluated oncologic outcomes in patients previously treated with BCG and ST who subsequently underwent radical cystectomy (RC). Methods We identified 378 patients with high-grade NMIBC who received at lea...
1 CitationsSource